Rosiglitazone API
CAS.NO:122320-73-4
structural formula:C18H19N3O3S
EINECS.no:924-121-1
Other names:Rosiglitazone;Rosiglitazone free base;ROSIGLITAZONE HCL;AVANDIA
Test Method:HPLC/UV/GC-MS
MOQ & Package: 10g,100g,1kg,5kg,10kg,25kg etc
Customer's rights and interests:Over 10kg, you can enjoy the service of giving away free samples.
Certificate：FDA,ISO,COA, HPLC, MSDS,TDS etc
Lead Time: 1-3 days
Shipping: DHL,Germany DHL,Germany DPD,UPS,USPS,FedEx,EMS,By Air,By Sea,multimodal transport etc
Store & Shelf life; Cool & dry place; 36 months
Company advantages: there are self-built overseas warehouses and third-party overseas warehouses on all continents.
- Product Description
Xi'an Faithful BioTech Co., Ltd: Your Trusted Rosiglitazone API Manufacturer & Supplier
Rosiglitazone API Powder has a targeted effect on improving insulin resistance and has been widely favored since its launch. There have been reports that the product has cardiovascular disease risks, but according to recent studies, compared with standard hypoglycemic Pharmaceutical raw material components metformin and sulfonylurea pharmaceutical ingredients, the Rosiglitazone provided by Xi'an Faithful BioTech Co., Ltd company does not increase the risk of heart attack. Based on this, on December 16, 2015, the FDA completely lifted prescription and sales restrictions on active ingredients containing Rosiglitazone.
Rosiglitazone API Introduction
ROSIGLITAZONE HCL is a thiazolidinedione insulin sensitizer, and its mechanism of action is related to the specific peroxisome proliferator activator gamma receptor (PPAR γ). Research has shown that the receptor is a protein that exists in the fat, skeletal muscle, and liver tissues of insulin sensitive tissues. Rosiglitazone API can lower blood glucose levels by increasing the sensitivity of skeletal muscle, liver, and adipose tissue to insulin, improving cell utilization of glucose, and significantly reducing fasting blood glucose and insulin and C-peptide levels. It also has a lowering effect on postprandial blood glucose and insulin. In addition, new evidence suggests that Rosiglitazone free base also has protective and improving effects on pancreatic beta cells.
Specifications
Item | Specifications | Results |
Appearance | White to off white powder | Conform |
Odor | Characteristic | Conform |
Melting point | 116°-119° | 117°-117.8° |
Residue on ignition | ≤0.1% | 0.05% |
LOD | ≤0.5% | 0.21% |
Water | ≤1% | 0.03% |
Related Related | Single impurity≤0.5% Total impurity≤1.0% | Conform |
Heavy Metal | ≤10 ppm | ＜10ppm |
Total of bacteria | ≤1000 cfu/g | Conform |
Fungi | ≤100 cfu/g | Conform |
Assay | ≥98.5% | 99.1% |
| Conclusion | Conform with enterprise specification （USP 41）. |
Why Choose Us?
According to our company's latest research, our Rosiglitazone raw material exerts cardiovascular protection through multiple mechanisms. Firstly, as a highly selective agonist of PPAR γ, it activates the PPAR γ nuclear receptor, regulates the transcription of insulin responsive genes involved in glucose production, transport, and utilization, improves insulin sensitivity, lowers blood glucose and lipid levels, thereby reducing cardiovascular metabolic burden.
Secondly, it has significant anti-inflammatory and antioxidant effects. It can inhibit inflammatory signaling pathways such as NF - κ B, reduce the levels of inflammatory factors such as C-reactive protein (CRP), serum amyloid A (SAA), and sE selectin, and alleviate vascular inflammatory responses. At the same time, it regulates the expression of heat shock protein 22 (HSP22), inhibits mitochondrial oxidative stress and dysfunction, and protects vascular endothelial cells.
Thirdly, it exerts a protective effect by improving endothelial function. It can increase the production of nitric oxide (NO), improve endothelium-dependent vasodilation, reduce blood pressure, inhibit the proliferation and migration of vascular smooth muscle cells, and delay the process of atherosclerosis. In addition, it can alleviate myocardial ischemia-reperfusion injury and reduce myocardial infarction area through the PI3K/Akt signaling pathway.
Finally, it exerts cardiovascular protection by regulating the renin-angiotensin system (RAS). It can downregulate the expression of angiotensin II type 1 receptor (AT1R), upregulate the expression of angiotensin II type 2 receptor (AT2R), inhibit angiotensin II induced proliferation of vascular smooth muscle cells, thereby reducing vascular remodeling and cardiac burden.
These multiple mechanisms work together to enable Rosiglitazone to have significant cardiovascular protective effects while controlling blood sugar.
In addition to the research results mentioned above, our company's products also adopt advanced production processes and have passed international authoritative certifications such as FDA and EDQM, meeting the regulatory requirements of major global markets. Each batch of products comes with a complete Certificate of Analysis (COA) to ensure that every step from raw material procurement to finished product delivery complies with Good Manufacturing Practice (GMP) requirements. In terms of market price, our products have obvious cost-benefit advantages, which is an ideal choice for you to research and develop diabetes Pharmaceutiucal Materials.
Our email address is:sales8@faithfulbio.com, Welcome your letter.
Typical adverse reactions
Abnormal liver function, dizziness, headache, diarrhea. Rosiglitazone API can cause an increase in plasma volume and cardiac hypertrophy caused by increased preload, leading to heart failure. There is a significant risk of hypoglycemia when combining other hypoglycemic pharmaceutical ingredients. Elderly patients may also have mild to moderate edema and mild anemia.
Quality Control:
R&D Results:
Packaging and Transportation:
After-Sales Service:
Qualification Certification:
Transaction Feedback:
Exhibition:
FAQ
Q1: What is its pharmacological mechanism of action?
It is a highly selective and potent agonist of peroxisome proliferator activated receptor gamma (PPAR gamma), with an EC50 of 60 nM and a Kd of 40 nM. It activates the PPAR gamma nuclear receptor, regulates the transcription of insulin responsive genes involved in glucose production, transport, and utilization, and increases the sensitivity of liver, adipose, and muscle tissues to insulin, thereby effectively controlling blood glucose levels. In addition, it can regulate fatty acid metabolism and has anti-inflammatory and antioxidant effects.
Q2: What is its hypoglycemic effect?
Clinical studies have shown that Rosiglitazone API can significantly reduce glycated hemoglobin (HbA1c) levels. Single drug treatment for 26 weeks can reduce HbA1c by 0.8% -1.5% and fasting blood glucose by 31.03mg/dL. Combined use with sulfonylurea or biguanide drugs can reduce insulin resistance by 3% -25%, with 94% of cases improving pancreatic beta cell function.
Q3: What should I do if I experience hypoglycemia during the use of high-quality Rosiglitazone?
If symptoms of hypoglycemia (such as sweating, palpitations, hunger, dizziness, etc.) occur, immediately consume sugary foods or drinks. If symptoms persist or worsen, seek medical attention immediately. When combined with insulin or sulfonylurea hypoglycemic agents, it may be necessary to adjust the treatment plan.
Contact us
Rosiglitazone raw powder is mainly used to treat type 2 diabetes clinically. It can be used alone or in combination with metformin and sulfonylurea medical materials, together with diet control and exercise, and can perfectly control the blood sugar of patients with type 2 diabetes. If you have research in this field, please leave a message to me via email::sales8@faithfulbio.com .
